Determination and stability of CP-31398 in plasma from experimental animals by LC-MS/MS

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 4, 2011, Pages 809-814

  Muzzio, Miguel ^a   Huang, Zhihua ^a   Johnson, William D ^a   Mccormick, David L ^a   Kapetanovic, Izet M ^b  

^a IIT RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CP 31398; LC MS MS; Method validation; Plasma; Stability

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; DRUG STRUCTURE; FEMALE; FLOW RATE; LIGHT EXPOSURE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETER; MASS SPECTROMETRY; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; VALIDATION STUDY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; CHROMATOGRAPHY, LIQUID; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; FEMALE; LIGHT; MALE; NEOPLASMS; PYRIMIDINES; RATS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84860388907     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.07.013     Document Type: Article

References (11)

1. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999, 286:2507-2510.
2. Brown C.J., Cheok C.F., Verma C.S., Lane D.P. Reactivation of p53: from peptides to small molecules. Trends in Pharmacological Sciences 2011, 32:53-62.
3. Rao C.V., Steele V.E., Swamy M.V., Patlolla J.M.R. Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Research 2009, 69:8175-8182.
4. Tang X., Zhu Y., Han L., Kim A.L., Kopelovich L., Bickers D.R., Athar M. CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. The Journal of Clinical Investigation 2007, 117:3753-3764.
5. Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 2003, 22:8233-8245.
6. Xu J., Timares L., Heilpern C., Weng Z., Li C., Xu H., Pressey J.G., Elmets C.A., Kopelovich L., Athar M. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Research 2010, 70:6566-6576.
7. Roh J.-L., Kang S.K., Minn I.L., Califano J.A., Sidransky D., Koch W.M. p53-reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncology 2011, 47:8-15.
8. Rao C.V., Swamy M.V., Patlolla J.M.R., Kopelovich L. Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice. Cancer Research 2008, 68:7670-7675.
9. Zachea N., Lambertac J.M.R., Rökaeusa N., Shen J., Hainaut P., Bergman J., Wimana K.G., Bykova Vl.J.N. Mutant p53 targeting by the low molecular weight compound STIMA-1. Molecular Oncology 2008, 2:70-80.
10. Rippin T.M., Bykov V.J., Freund S.M., Selivanova G., Wiman K.G., Fersht A.R. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002, 28:2119-2129.
11. Guidance for Industry: Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), May 2001. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.